Unlike flu, COVID-19 attacks DNA in the heart: new research
Covid19-Sources
SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients - 2020.08.25.265561v1.full.pdf
Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot
COVID-19 and children
A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19
Bert Weingarten on Twitter
Incidence, risk and severity of SARS-CoV-2 reinfections in children and adolescents: a population-level study between March 2020 and July 2022
Long-COVID bei Kindern
Ralf Wittenbrink on Twitter
Life expectancy changes since COVID-19
"Neue Phase der Pandemie" - Experte warnt vor zwei Dingen
Effectiveness of Monovalent mRNA Vaccines Against ...
SARS-CoV-2 und die Laborursprungshypothese - Ist was dran?
Nicht die Impfung, sondern Covid-19 macht Männer unfruchtbar
LangzeitCOVID on Twitter
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents
Jan Hartmann on Twitter
Lasting Lung Damage Seen in Children and Teens after COVID
Pulmonary Dysfunction after Pediatric COVID-19
Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies
Addiction drug shows promise lifting long COVID brain fog, fatigue
WHO chief scientist sounds alarm on new Covid wave due to XXB variant
Why Experts Are Warning About 'Troublesome' COVID Variants BQ.1 and BQ.1.1
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
Why scientists are keeping an eye on two new Omicron subvariants and what they could mean for Ontario
Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism - Molecular Medicine
Vaccines to treat cancer possible by 2030, say BioNTech founders
RKI - Influenza - Wie hoch ist die Wirksamkeit der Influenza-Impfung?
Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies